| 181.2 1.73 (0.96%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 214.49 | 1-year : | 250.52 |
| Resists | First : | 183.63 | Second : | 214.49 |
| Pivot price | 179.42 |
|||
| Supports | First : | 177.79 |
Second : | 174.17 |
| MAs | MA(5) : | 178.75 |
MA(20) : | 179.93 |
| MA(100) : | 171.62 |
MA(250) : | 164.24 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4  |
| %K %D | K(14,3) : | 60.5 |
D(3) : | 48.2 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 183.63 | Low : | 142.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BBH ] has closed below upper band by 29.1%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 181.31 - 181.84 | 181.84 - 182.44 |
| Low: | 177.65 - 178.32 | 178.32 - 179.06 |
| Close: | 180.03 - 181.03 | 181.03 - 182.15 |
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Wed, 14 Aug 2024
IBB: 3 Biotech ETFs for a Diversified Portfolio - StockNews.com
Tue, 23 Jul 2024
BBH: Buy Rating, As Tech Investors Look Beyond FAANG (NASDAQ:BBH) - Seeking Alpha
Fri, 28 Jun 2024
7 Best Biotech ETFs to Buy Now | Investing - U.S News & World Report Money
Tue, 25 Jun 2024
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 - InvestorPlace
Thu, 04 Jan 2024
Has Biotechnology Bottomed Out? - Master Investor
Wed, 03 Jan 2024
AI Advancements Could Be Boon for Biotech Industry - ETF Trends
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|